We’re excited to announce our collaboration with CancerWorld magazine! This special issue is about the 25th anniversary of an oral medication for chronic myeloid leukemia that transformed treatment, diagnostics, access, and patient advocacy.
It features articles from the global community, including clinicians, researchers, patients, and advocates. Learn more about how a woman living with CML started helping others navigate their diagnosis, or the successes and challenges that come with providing treatment in a low-income country. Each voice has something special to share.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
Max adds three new members to the Board of Directors, increasing the seats from eight to 11 In addition, Max has added 10 new team members in 2024 to support growing patient reach, collaboration with partners, and new disease areas This expansion will ensure Max can meet its strategic goals, including treating more patients, amplifying….
The Max Foundation is pleased to announce the hiring of Wilma Comenat as Vice President of Development of The Max Foundation. Wilma has more than 20 years of experience in the nonprofit sector leading development teams and driving major donor fundraising initiatives. Her previous roles include the Associate Executive Director of JDRF Greater Northwest, Regional Director of Lupus Foundation of America, Inc.’s Pacific Northwest region, and Deputy Executive Director of The Leukemia & Lymphoma Society.
The Max Foundation is proud to announce it has signed an expanded collaboration agreement with Bristol-Myers Squibb – a committed pharmaceutical partner and member of our humanitarian pact.
